Similar articles

• Clinical trials in autism spectrum disorder: evidence, challenges and future directions.

  Anagnostou E. Anagnostou E. Curr Opin Neurol. 2018 Apr;31(2):119-125. doi: 10.1097/WCO.0000000000000542. Curr Opin Neurol. 2018. PMID: 29389748 Review.
• Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.

  Joshi G, Wilens T, Firmin ES, Hoskova B, Biederman J. Joshi G, et al. J Psychopharmacol. 2021 Mar;35(3):203-210. doi: 10.1177/0269881120972336. Epub 2020 Dec 21. J Psychopharmacol. 2021. PMID: 33349107
• [Autism and attention deficit hyperactivity disorder: pharmacological intervention].

  Fernández-Jaén A, Martín Fernández-Mayoralas D, Fernández-Perrone AL, Calleja-Pérez B, Muñoz-Jareño N, López-Arribas S. Fernández-Jaén A, et al. Rev Neurol. 2013 Sep 6;57 Suppl 1:S205-10. Rev Neurol. 2013. PMID: 23897149 Review. Spanish.
• Methylphenidate an effective treatment for ADHD?

  McDougle CJ. McDougle CJ. J Autism Dev Disord. 2004 Oct;34(5):593-4. J Autism Dev Disord. 2004. PMID: 15628613 No abstract available.
• Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.

  Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P. Cortese S, et al. CNS Drugs. 2015;29(10):865-77. doi: 10.1007/s40263-015-0266-7. CNS Drugs. 2015. PMID: 26293742 Clinical Trial.